Stock Events

Stock Events

BioCardia 

$1.21
0
-$0.05-3.97% Monday 07:46

Statistics

Day High
1.22
Day Low
1.2
52W High
-
52W Low
-
Volume
568
Avg. Volume
-
Mkt Cap
12.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-0.24
-0.16
-0.08
0
Expected EPS
-0.165
Actual EPS
N/A

Financials

-13,700%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
116,000Revenue
-15.89MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BCDA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap116.33B
Medtronic operates in the cardiovascular space, offering products that compete directly with BioCardia's heart disease treatments.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories provides a wide range of medical devices, including those for cardiovascular health, directly competing with BioCardia's offerings.
Boston Scientific
BSX
Mkt Cap149.24B
Boston Scientific Corporation specializes in medical devices for various conditions, including cardiovascular, making it a direct competitor.
Edwards Lifesciences
EW
Mkt Cap48.41B
Edwards Lifesciences focuses on heart valves and hemodynamic monitoring, competing in the cardiovascular space with BioCardia.
Intuitive Surgical
ISRG
Mkt Cap189.4B
Intuitive Surgical offers robotic-assisted surgical systems that can be used in cardiovascular procedures, indirectly competing with BioCardia's treatments.
Baxter International
BAX
Mkt Cap9.49B
Baxter International Inc. provides a range of medical devices and therapies, including for cardiovascular diseases, competing with BioCardia.
Zimmer Biomet
ZBH
Mkt Cap19.92B
Zimmer Biomet Holdings, Inc., while primarily focused on musculoskeletal healthcare, has expanded into new areas, potentially competing with BioCardia.
Stryker
SYK
Mkt Cap136.19B
Stryker Corporation, known for medical and surgical equipment, has products that can be used in cardiovascular care, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its medical devices segment, offers products that can compete in the cardiovascular space with BioCardia.
Integra Lifesciences
IART
Mkt Cap935.48M
Integra LifeSciences, a provider of regenerative technologies, could compete in the cardiovascular and wound care markets relevant to BioCardia.

About

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Show more...
CEO
ISIN
US09060U6064

Listings

XNAS
US
BCDA
F
DE
6JU0.F
BOATS
BOATS
BCDA.BOATS

0 Comments

Share your thoughts

FAQ

What is BioCardia stock price today?▼
The current price of BCDA.BOATS is $1.21 USD — it has decreased by -3.97% in the past 24 hours. Watch BioCardia stock price performance more closely on the chart.
What is BioCardia stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange BioCardia stocks are traded under the ticker BCDA.BOATS.
What is BioCardia market cap?▼
Today BioCardia has the market capitalization of 12.84M
When is the next BioCardia earnings date?▼
BioCardia is going to release the next earnings report on May 13, 2026.
What were BioCardia earnings last quarter?▼
BCDA.BOATS earnings for the last quarter are 0 USD per share, whereas the estimation was -0.17 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is BioCardia revenue for the last year?▼
BioCardia revenue for the last year amounts to 116,000 USD.
What is BioCardia net income for the last year?▼
BCDA.BOATS net income for the last year is -15.89M USD.
When did BioCardia complete a stock split?▼
BioCardia has not had any recent stock splits.